Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo

References

• Altomare DA Testa JR Perturbations of the AKT signaling pathway in human cancer Oncogene 2005 24 50 7455 7464 16288292
   PubMed Web of Science ®Google Scholar
• Altun M Fandi A Dupuis O Cvitkovic E Krajina Z Eschwege F Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects Int J Radiat Oncol Biol Phys 1995 32 3 859 877 7790274
   PubMed Web of Science ®Google Scholar
• Cheng SH Jian JJ Tsai SY Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy Int J Radiat Oncol Biol Phys 2000 48 5 1323 1330 11121629
   PubMed Web of Science ®Google Scholar
• Yamashita S Kondo M Hashimoto S Squamous cell carcinoma of the nasopharynx. An analysis of failure patterns after radiation therapy Acta Radiol Oncol 1985 24 4 315 320 2994387
   PubMed Web of Science ®Google Scholar
• Ranson M Hammond LA Ferry D ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 2002 20 9 2240 2250 11980995
   PubMed Web of Science ®Google Scholar
• Chua DT Wei WI Wong MP Sham JS Nicholls J Au GK Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma Head Neck 2008 30 7 863 867 18213730
   PubMed Web of Science ®Google Scholar
• Ma B Hui EP King A A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy Cancer Chemother Pharmacol 2008 62 1 59 64 17762933
   PubMed Web of Science ®Google Scholar
• Ma BB Lui VW Poon FF Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response Invest New Drugs 2010 28 3 326 333 19756373
   PubMed Web of Science ®Google Scholar
• Bellacosa A Testa JR Staal SP Tsichlis PN A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region Science 1991 254 5029 274 277 1833819
   PubMed Web of Science ®Google Scholar
• Manning BD Cantley LC AKT/PKB signaling: navigating downstream Cell 2007 129 7 1261 1274 17604717
   PubMed Web of Science ®Google Scholar
• Yip WK Leong VC Abdullah MA Yusoff S Seow HF Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma Oncol Rep 2008 19 2 319 328 18202777
   PubMed Web of Science ®Google Scholar
• Mei YP Zhou JM Wang Y Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells Cell Cycle 2007 6 11 1379 1385 17507800
   PubMed Web of Science ®Google Scholar
• Chou J Lin YC Kim J Nasopharyngeal carcinoma – review of the molecular mechanisms of tumorigenesis Head Neck 2008 30 7 946 963 18446839
   PubMed Web of Science ®Google Scholar
• Mainou BA Everly DNJr Raab-Traub N Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K Oncogene 2005 24 46 6917 6924 16007144
   PubMed Web of Science ®Google Scholar
• Morrison JA Raab-Traub N Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling J Virol 2005 79 4 2375 2382 15681438
   PubMed Web of Science ®Google Scholar
• Pedrero JM Carracedo DG Pinto CM Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma Int J Cancer 2005 114 2 242 248 15543611
   PubMed Web of Science ®Google Scholar
• Yan L MK-2206: a potent oral allosteric AKT inhibitor Presented at: 100th Annual Meeting of the American Association for Cancer Research April 18–22, 2009 Denver, CO Abstract DDT01–1
   Google Scholar
• Yap TA Yan L Patnaik A First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors J Clin Oncol 2011 29 35 4688 4695 22025163
   PubMed Web of Science ®Google Scholar
• Zhao YY Xue C Jiang W Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab J Thorac Oncol 2012 7 1 71 75 22011670
   PubMed Web of Science ®Google Scholar
• Wang H Zhang Q Wen Q Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway Cell Signal 2012 24 1 17 24 21906675
   PubMed Web of Science ®Google Scholar
• Yap TA Walton MI Hunter LJ Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930 Mol Cancer Ther 2011 10 2 360 371 21191045
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F Gonzalez-Angulo AM Targeting the mTOR signaling network for cancer therapy J Clin Oncol 2009 27 13 2278 2287 19332717
   PubMed Web of Science ®Google Scholar
• Takeuchi H Kondo Y Fujiwara K Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors Cancer Res 2005 65 8 3336 3346 15833867
   PubMed Web of Science ®Google Scholar
• Wu H Yang JM Jin S Zhang H Hait WN Elongation factor-2 kinase regulates autophagy in human glioblastoma cells Cancer Res 2006 66 6 3015 3023 16540650
   PubMed Web of Science ®Google Scholar
• Mizushima N Methods for monitoring autophagy Int J Biochem Cell Biol 2004 36 12 2491 2502 15325587
   PubMed Web of Science ®Google Scholar
• Knowles JA Golden B Yan L Carroll WR Helman EE Rosenthal EL Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma Laryngoscope 2011 121 11 2359 2365 22020886
   PubMed Web of Science ®Google Scholar
• Ma BB Lui VW Hui CW Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines Invest New Drugs 2013 31 3 567 575 23143779
   PubMed Web of Science ®Google Scholar
• Jiao P Zhou YS Yang JX MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death Mol Cell Biochem 2013 382 1–2 217 224 23797319
   PubMed Web of Science ®Google Scholar
• Degtyarev M De Mazière A Orr C Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents J Cell Biol 2008 183 1 101 116 18838554
   PubMed Web of Science ®Google Scholar
• Kundu M Thompson CB Macroautophagy versus mitochondrial autophagy: a question of fate? Cell Death Differ 2005 12 suppl 2 1484 1489 16247496
   PubMed Web of Science ®Google Scholar
• Cheng Y Ren X Zhang Y eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206 Cancer Res 2011 71 7 2654 2663 21307130
   PubMed Web of Science ®Google Scholar